Apotex Expands Canadian Ophthalmology Portfolio With Health Canada's Approval of Clobivis

Key Takeaways

• Apotex announced that Health Canada has approved Clobivis (clobetasol propionate ophthalmic suspension 0.05%) for the treatment of postoperative inflammation and pain following cataract surgery
• The company stated that the product’s approval marks a meaningful enhancement to its growing ophthalmology portfolio
• The approval supports Apotex’s strategy to increase Canadian patients’ access to innovative ophthalmic treatments

Apotex announced that Health Canada has approved Clobivis (clobetasol propionate ophthalmic suspension 0.05%), which is indicated for the treatment of postoperative inflammation and pain following cataract surgery.

According to Apotex, Clobivis, licensed from Formosa, is formulated using nanoparticle technology to deliver a uniform ophthalmic suspension. The company stated that the product’s approval marks a meaningful enhancement to its growing ophthalmology portfolio and reinforces its commitment to expanding access to treatment options for Canadian patients.

“Apotex seeks to ensure patients have access to innovative treatments," said Martin Arès, president, Apotex Canada and Rest of World. “The approval of Clobivis is another milestone in broadening the availability of ophthalmology medicines through strategic partnerships that support ophthalmic care for Canadians, and it reflects our journey of health strategy to expand access to new therapies.”

Health care professionals should refer to the complete product monograph for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements.

Originally published online on Eyewire+.